RevBio

Executive Summary

RevBio is a private US medical device and regenerative medicine company developing TETRANITE, a patented synthetic adhesive biomaterial for bone repair. Inspired by the sandcastle worm, TETRANITE bonds bone-to-bone and bone-to-metal in wet surgical fields, providing rapid mechanical stability and controlled biodegradability that is replaced by new bone. Founded in 2011 and headquartered in Lowell, Massachusetts, the company aims to transform bone repair procedures. While no specific funding or pipeline data is available, the technology addresses a significant unmet need in orthopedic and trauma surgery. RevBio's progress likely depends on clinical trial outcomes and regulatory milestones.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Pivotal Clinical Trial for TETRANITE70% success
• Q2 2026FDA Breakthrough Device Designation80% success
• Q3 2026Strategic Partnership or Licensing Agreement60% success